France-headquartered Groupe Novasep SAS provides manufacturing solutions for life sciences molecules and fine chemicals. Its US-based unit TangenX Technology Corporation produces single-use tangential flow filtration (“TFF”) cassettes and hardware used in downstream biopharmaceutical manufacturing processes.
For acquirer Repligen, a NASDAQ-listed life sciences company focused on bioprocessing technology, TangenX strengthened its position as a leader in single-use bioprocessing technologies and extended its reach into downstream processes, where disposables are increasingly being adopted by biopharmaceutical manufacturers.
Groupe Novasep, based in Lyon, France, is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules and fine chemicals. Novasep’s unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries.
Bryan, Garnier & Co advised Groupe Novasep on the divestiture, which saw substantial strategic interest in TangenX’s technology and a valuation that exceeded the seller’s expectations.